biote Corp Acquires Asteria Health

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals completed its previously announced acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, net of Astria cash at closing. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor in Phase 3, to BioCryst’s hereditary angioedema (HAE) portfolio and provides BioCryst with Astria’s early-stage atopic dermatitis program STAR0310 for further strategic alternatives.

Haymaker Acquisition Corp. III Merges with Biote

June 3, 2022

Healthcare Services

Haymaker Acquisition Corp. III, a publicly traded SPAC, completed its merger with consumer-directed hormone optimization company Biote (transaction announced Dec 13, 2021; closed May 27, 2022). Biote operates a platform that trains and certifies practitioners and provides practice management software, marketing support and branded nutraceutical products, and had grown a network of roughly 4,700 Biote-certified practitioners in the U.S.

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.

Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Deal

October 11, 2025

Biotechnology

Bristol Myers Squibb (BMS) has entered into an agreement to acquire Orbital Therapeutics, a privately held biotechnology company developing RNA medicines. The $1.5 billion cash deal will give BMS Orbital’s lead candidate OTX-201 and its proprietary RNA platform, supporting BMS’s efforts to advance in vivo CAR T and immunotherapy approaches.

Miura Partners Acquires HTBA (HealthTech BioActives)

November 5, 2024

Biotechnology

Miura Partners has signed an agreement to acquire HTBA (HealthTech BioActives), a Barcelona-headquartered producer of flavonoids and active vitamin B12 used across pharmaceutical, nutraceutical, food & beverage and animal nutrition markets. Miura will pursue organic and inorganic initiatives to consolidate HTBA as a leading platform for natural ingredients; the deal is the third investment from Miura Fund IV and is pending approval from the Spanish regulator.

AstraZeneca to Acquire EsoBiotec

March 18, 2025

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company developing in vivo cell therapies. The deal is valued at up to $1 billion on a cash and debt-free basis, with an initial $425 million payment upon closing plus up to $575 million in contingent milestone consideration. The transaction is expected to close in Q2 2025, subject to regulatory approvals.